GEMSIT wraps up purchase of Triple G Systems

TriMed Staff | | Health Imaging | Diagnostic Imaging
GE Medical Systems Information Technologies (GEMSIT) has closed on its acquisition of laboratory information systems company Triple G Systems Group Inc. for approximately US$2.40 per share.

GEMSIT President and CEO Dow Wilson says the addition of Triple G will help the Milwaukee company develop a clinical information system for the next generation of electronic medical records. Triple G's lab information systems are licensed to more than 110 healthcare facilities, representing more than 450 clinical labs in the United States, Canada, United Kingdom and the Asia-Pacific region.

With its acquisition, Triple G will become a private company no longer listed on its hometown Toronto Stock Exchange.

TriMed Staff

Related Content

First human X-rays in space to take place during upcoming SpaceX mission
Mycoplasma pneumonia: Experts highlight imaging findings linked to the pediatric diagnosis
AI rules out abnormal findings on chest X-rays, significantly reducing workloads
Older adults among the walking wounded with incident TBI
Philips moves digital pathology to the cloud with AWS
PHOTO GALLERY: What does fetal medical imaging look like?

Around the web

Cardiovascular Business
GE HealthCare launches new cardiac CT scanner with advanced AI capabilities

GE HealthCare designed the new-look Revolution Vibe CT scanner to help hospitals and health systems embrace CCTA and improve overall efficiency.

Cardiovascular Business
Bracco updates HeartSee coronary flow capacity software with new diagnostic features

Clinicians have been using HeartSee to diagnose and treat coronary artery disease since the technology first debuted back in 2018. These latest updates, set to roll out to existing users, are designed to improve diagnostic performance and user access.

Cardiovascular Business
Key trends in diagnostic heart testing: CT on the rise as some traditional techniques fall out of favor

The cardiac technologies clinicians use for CVD evaluations have changed significantly in recent years, according to a new analysis of CMS data. While some modalities are on the rise, others are being utilized much less than ever before.